. Author manuscript; available in PMC: 2015 Dec 15.

Published in final edited form as: Cancer. 2014 Aug 5;120(24):3902–3913. doi: 10.1002/cncr.28963

Table 2.

1. IF (BGN ≤ 245 μg/ml)&(MPO ≤ 120 ng/ml)&(ANXA6 ≤ 6 μg/ml) THEN (Class = Normal)

Posterior Probability=0.939, P=0.0, TP=30, FP=1

2. IF (BGN ≤ 245 μg/ml)&(MPO ≤ 120 ng/ml)&(ANXA6 > 6 μg/ml) THEN (Class = Normal)

Posterior Probability=0.75, P=0.064, TP=11, FP=3

3. IF (BGN ≤ 245 μg/ml)&(MPO > 120 ng/ml)&(ANXA6 ≤ 6 μg/ml) THEN (Class = Normal)

Posterior Probability=0.75, P=0.317, TP=2, FP=0

4. IF (BGN ≤ 245 μg/ml)&(MPO > 120 ng/ml)&(ANXA6 > 6 μg/ml) THEN (Class = Cancer)

Posterior Probability=0.667, P=0.434, TP=1, FP=0

5. IF (BGN > 245 μg/ml)&(S100A9 ≤ 3 ng/ml)&(ANXA6 ≤ 6 μg/ml) THEN (Class = Normal)

Posterior Probability=0.571, P=0.624, TP=3, FP=2

6. IF (BGN > 245 μg/ml)&(S100A9 ≤ 3 ng/ml)&(ANXA6 > 6 μg/ml) THEN (Class = Normal)

Posterior Probability=0.8, P=0.177, TP=3, FP=0

7. IF (BGN > 245 μg/ml)&(S100A9 > 3 ng/ml)&(MPO ≤ 120 ng/ml)&(ANXA6 ≤ 6 μg/ml)

THEN (Class = Normal)

Posterior Probability=0.5, P=0.777, TP=3, FP=3

8. IF (BGN > 245 μg/ml)&(S100A9 > 3 ng/ml)&(MPO ≤ 120 ng/ml)&(ANXA6 > 6 μg/ml)

THEN (Class = Cancer)

Posterior Probability=0.765, P=0.002, TP=12, FP=3

9. IF (BGN > 245 μg/ml)& (S100A9 > 3 ng/ml)&(MPO > 120 ng/ml) THEN (Class = Cancer)

Posterior Probability=0.917, P=0.0, TP=21, FP=1

Serum protein biomarkers used (4): S100A9, ANXA6, BGN, MPO